Get the Stockscreener App
1.72
9.95%
-0.19
Pre-market:
1.80
0.08
+4.65%
Prime Medicine Inc stock is traded at $1.72, with a volume of 2.03M.
It is down -9.95% in the last 24 hours and down -33.72% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$1.91
Open:
$1.91
24h Volume:
2.03M
Relative Volume:
1.83
Market Cap:
$225.60M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-0.7926
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-25.22%
1M Performance:
-33.72%
6M Performance:
-57.95%
1Y Performance:
-78.31%
1-Day Range:
$1.71
$1.96
1-Week Range:
$1.71
$2.47
52-Week Range:
$1.71
$8.27
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
1.72 | 225.60M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com
Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex
Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register
Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World
Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India
Prime Medicine’s (PRME) Buy Rating Reaffirmed at HC Wainwright - Defense World
Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World
Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks
Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks
Prime Medicine’s (PRME) “Outperform” Rating Reiterated at Wedbush - Defense World
ARK Investment Management LLC Reduces Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine Reports 2024 Financial Results and Progress - TipRanks
Prime Medicine, Inc. SEC 10-K Report - TradingView
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Can Prime Medicine's $204M Cash Boost Fuel Its Gene Editing Breakthrough? Clinical Data Coming in 2025 - StockTitan
Prime Medicine (NYSE:PRME) vs. Bio-Techne (NASDAQ:TECH) Critical Analysis - Defense World
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Contrasting Prime Medicine (NYSE:PRME) and Achilles Therapeutics (NASDAQ:ACHL) - Defense World
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Comparing Qiagen (NYSE:QGEN) & Prime Medicine (NYSE:PRME) - Defense World
Sumitomo Mitsui Trust Group Inc. Has $9.02 Million Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine (NYSE:PRME) Raised to Sell at StockNews.com - Defense World
Analysts review Prime Medicine Inc’s rating - Knox Daily
Closing Figures: Prime Medicine Inc (PRME)’s Negative Finish at 2.47, Down -1.98 - The Dwinnex
There is no way Prime Medicine Inc (PRME) can keep these numbers up - SETE News
Prime Medicine, Inc. (NYSE:PRME) Receives $13.13 Average PT from Brokerages - Armenian Reporter
Prime Medicine: Gene Editing Company, Risky Investment (NASDAQ:PRME) - Seeking Alpha
Metric Analysis: Prime Medicine Inc (PRME)’s Key Ratios in the Limelight - The Dwinnex
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.13 - MarketBeat
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13 - Defense World
Nisa Investment Advisors LLC Buys 12,507 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Thermo Fisher to Cut 300 People Across 2 Massachusetts Sites - BioSpace
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm -January 30, 2025 at 12:27 pm EST - Marketscreener.com
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PR Newswire
PBM Prime Therapeutics to Pay $10 Million Antitrust Case Over Price-Fixing Scheme with Express Scripts, Inc. - Policy & Medicine
In Vivo’s Deal Of The Year: Cast Your Vote! - Citeline News & Insights
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Alliance for Regenerative Medicine: Field growing, cost still an issue - BioWorld Online
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):